Poison Centers See 1,200% Surge in Kratom-Related Calls Over 10 Years

Why It Matters

The dramatic rise in kratom-related poison‑center calls signals a growing public‑health threat that intersects with the broader opioid crisis. Synthetic variants like 7‑OH amplify the risk of dependence and overdose, especially when users combine kratom with other depressants. Without timely regulatory action, hospitals may face increasing burdens from preventable admissions, and the lack of clear labeling could perpetuate consumer confusion and harm. Moreover, the data underscore the value of poison‑center surveillance as a real‑time barometer for emerging drug trends. Strengthening this infrastructure could enable faster policy responses, potentially averting thousands of serious medical outcomes and saving lives.

Key Takeaways

• Poison centers logged 14,449 kratom-related calls from 2015‑2025, a 1,200% increase.
• 2025 alone accounted for 3,434 calls, representing over 23% of the decade total.
• Hospitalizations for kratom alone rose from 43 to 538; combined‑use cases rose from 40 to 549.
• Serious health outcomes jumped from 76 to 919 for solo users and from 51 to 725 for combined users.
• 233 deaths were recorded over the ten‑year period, with 184 involving multiple substances.

Pulse Analysis

The surge in kratom-related incidents reflects a broader shift in the supplement market toward unregulated, high‑potency products that blur the line between dietary aid and controlled substance. Historically, kratom occupied a gray area, marketed for pain relief and energy without rigorous safety testing. The introduction of synthetic 7‑OH, however, has transformed it into a de facto opioid analog, attracting users seeking stronger effects while bypassing existing drug‑control frameworks.

From a market perspective, the rapid growth of kratom sales—especially in powdered, capsule, and beverage forms—has outpaced regulatory oversight. Companies have capitalized on loopholes, often labeling products as “herbal” or “natural” despite containing potent synthetic compounds. This dynamic mirrors earlier episodes with novel psychoactive substances, where lagging policy allowed widespread distribution before health consequences became evident. The current data suggest that poison‑center alerts are now the primary source of intelligence on kratom’s impact, highlighting a need for more proactive surveillance mechanisms.

Looking forward, policymakers face a delicate balance: imposing restrictions that protect public health without stifling legitimate research into kratom’s therapeutic potential. Federal scheduling could curb the most dangerous formulations, but it may also drive the market underground, complicating monitoring efforts. State‑level bans, like Los Angeles County’s recent prohibition, provide a testing ground for targeted interventions. Ultimately, a coordinated strategy—combining stricter labeling, consumer education, and enhanced data sharing between poison centers, hospitals, and regulators—will be essential to reverse the upward trend and safeguard vulnerable populations.